Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Depreciation: 2018-2023

Historic Accumulated Depreciation for Bicycle Therapeutics (BCYC) over the last 6 years, with Dec 2023 value amounting to $13.4 million.

  • Bicycle Therapeutics' Accumulated Depreciation rose 59.03% to $16.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $16.6 million, marking a year-over-year increase of 59.03%. This contributed to the annual value of $13.4 million for FY2023, which is 70.33% up from last year.
  • As of FY2023, Bicycle Therapeutics' Accumulated Depreciation stood at $13.4 million, which was up 70.33% from $7.9 million recorded in FY2022.
  • Over the past 5 years, Bicycle Therapeutics' Accumulated Depreciation peaked at $13.4 million during FY2023, and registered a low of $2.7 million during FY2019.
  • Over the past 3 years, Bicycle Therapeutics' median Accumulated Depreciation value was $7.9 million (recorded in 2022), while the average stood at $8.7 million.
  • Data for Bicycle Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 70.33% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Bicycle Therapeutics' Accumulated Depreciation stood at $2.7 million in 2019, then skyrocketed by 50.28% to $4.0 million in 2020, then increased by 19.05% to $4.8 million in 2021, then surged by 63.81% to $7.9 million in 2022, then skyrocketed by 70.33% to $13.4 million in 2023.